327 related articles for article (PubMed ID: 26899376)
1. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials.
Diao WQ; Shen N; Yu PX; Liu BB; He B
Vaccine; 2016 Mar; 34(13):1496-1503. PubMed ID: 26899376
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
Walters JA; Tang JN; Poole P; Wood-Baker R
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD001390. PubMed ID: 28116747
[TBL] [Abstract][Full Text] [Related]
3. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for preventing pneumococcal infection in adults.
Moberley SA; Holden J; Tatham DP; Andrews RM
Cochrane Database Syst Rev; 2008 Jan; (1):CD000422. PubMed ID: 18253977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-Analysis.
Schiffner-Rohe J; Witt A; Hemmerling J; von Eiff C; Leverkus FW
PLoS One; 2016; 11(1):e0146338. PubMed ID: 26761816
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis.
Kraicer-Melamed H; O'Donnell S; Quach C
Vaccine; 2016 Mar; 34(13):1540-1550. PubMed ID: 26899372
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
8. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
9. Vaccines for preventing pneumococcal infection in adults.
Dear K; Holden J; Andrews R; Tatham D
Cochrane Database Syst Rev; 2003; (4):CD000422. PubMed ID: 14583920
[TBL] [Abstract][Full Text] [Related]
10. Vaccines for preventing pneumococcal infection in adults.
Moberley S; Holden J; Tatham DP; Andrews RM
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD000422. PubMed ID: 23440780
[TBL] [Abstract][Full Text] [Related]
11. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Plosker GL
Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
[TBL] [Abstract][Full Text] [Related]
12. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
13. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
Ludwig E; Mészner Z;
Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
16. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia.
Sanz-Herrero F; Gimeno-Cardona C; Tormo-Palop N; Fernández-Fabrellas E; Briones ML; Cervera-Juan Á; Blanquer-Olivas J
Vaccine; 2016 Apr; 34(15):1847-52. PubMed ID: 26845737
[TBL] [Abstract][Full Text] [Related]
17. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study.
Krueger P; St Amant O; Loeb M
BMC Geriatr; 2010 Jun; 10():44. PubMed ID: 20591180
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.
Cornu C; Yzèbe D; Léophonte P; Gaillat J; Boissel JP; Cucherat M
Vaccine; 2001 Sep; 19(32):4780-90. PubMed ID: 11535330
[TBL] [Abstract][Full Text] [Related]
19. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
20. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies.
Vlachopoulos CV; Terentes-Printzios DG; Aznaouridis KA; Pietri PG; Stefanadis CI
Eur J Prev Cardiol; 2015 Sep; 22(9):1185-99. PubMed ID: 25252595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
